Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on NovoCure (NASDAQ:NVCR) but lowers the price target from $42 to $40.
July 26, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on NovoCure but lowers the price target from $42 to $40.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on NVCR's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100